ANSWER: C

Rationale:

Perioperative management of trihexyphenidyl in a patient undergoing bowel surgery requires weighing two competing risks rather than applying a simple rule. The risk of continuation is that anticholinergic blockade of gastrointestinal smooth muscle — mediated by M3 receptor blockade — reduces GI motility throughout the gut and can compound the postoperative ileus that follows any abdominal surgery, and particularly bowel surgery where handling of the intestine and anastomosis construction already significantly disrupt GI motility. Prolonging postoperative ileus delays return to oral intake, increases risk of anastomotic complications, prolongs hospitalization, and limits the patient's ability to restart his full PD medication regimen. The risk of discontinuation is anticholinergic withdrawal — nausea, sweating, anxiety — and rebound worsening of tremor that can impair early postoperative mobilization and rehabilitation. Neither risk is trivial, and neither a blanket continuation nor blanket discontinuation policy is optimal. The most defensible approach is a case-by-case discussion with the surgical and anesthesia teams, dose reduction rather than complete cessation if feasible, and a plan to resume full dosing promptly as oral intake returns. Option C correctly frames this as a genuine clinical dilemma requiring individualized decision-making and identifies the key trade-offs.

• Option A: Option A is incorrect; recommending complete preoperative discontinuation without acknowledging withdrawal risk and tremor rebound overstates one side of the trade-off and ignores established anticholinergic discontinuation principles.
• Option B: Option B is incorrect; the assertion that anticholinergic GI effects are not a meaningful additional risk after bowel surgery is clinically indefensible — anticholinergic-induced gut dysmotility is a well-recognized contributor to postoperative ileus, and bowel surgery patients are particularly vulnerable.
• Option D: Option D is incorrect; anticholinergic effects on GI motility are not limited to the colon — muscarinic blockade impairs motility throughout the gastrointestinal tract including the small bowel, and small bowel recovery is indeed the key determinant of return of function after abdominal surgery.
• Option E: Option E is incorrect; glycopyrrolate does not penetrate the CNS because of its quaternary structure, but peripheral anticholinergic activity does not prevent central anticholinergic withdrawal — tremor in PD is generated by central basal ganglia circuits, not peripheral muscarinic receptors, and peripheral anticholinergic maintenance cannot substitute for central muscarinic blockade in preventing withdrawal tremor.

ANSWER: A

Rationale:

This case illustrates a clinically important pharmacokinetic-clinical intersection. Gocovri at 68.5 mg was appropriately prescribed for a CrCl of 32 mL/min — the recommended initial dose for the moderate renal impairment band (30 to 59 mL/min). As renal function worsens, amantadine accumulates because it is renally eliminated. The intercurrent dehydration has dropped her CrCl to 28 mL/min, moving her into the severe renal impairment band (15 to 29 mL/min), where 68.5 mg remains the maximum recommended dose but the falling clearance raises steady-state exposure. Gocovri is contraindicated only in end-stage renal disease (CrCl below 15 mL/min); this patient has not reached that threshold, but her declining clearance is sufficient to drive accumulation to toxic concentrations. The temporal relationship between drug initiation five days ago and onset of hallucinations two days later is highly consistent with amantadine accumulation as the cause — amantadine's half-life is extended in renal impairment, and as renal function declined further, plasma concentrations rose above the threshold for CNS toxicity. The correct response is to discontinue Gocovri, address the dehydration to restore renal function, and monitor for resolution of hallucinations and confusion as amantadine clears. Once renal function and mental status recover, restarting with careful re-dosing appropriate to her renal band is reasonable. Option A correctly identifies the shift into the severe band, the accumulation mechanism, and the management approach.

• Option B: Option B is incorrect; adding quetiapine for hallucinations while continuing a drug that is accumulating as renal function declines treats the symptom while perpetuating the cause — the priority is removing the offending drug, not adding antipsychotic coverage.
• Option C: Option C is incorrect; the CrCl decline from 32 to 28 mL/min is clinically significant because it moves her into the severe renal impairment band and reflects falling clearance of a renally eliminated drug, not merely statistical noise; furthermore, amantadine accumulation can produce CNS toxicity within days in the setting of declining renal function, not only after two weeks.
• Option D: Option D is incorrect; uptitrating a drug in a patient who is already showing signs of toxicity from accumulation is dangerous and contraindicated — dose escalation would worsen toxicity, not clarify it.
• Option E: Option E is incorrect; the temporal relationship between Gocovri initiation and hallucination onset, combined with the documented CrCl decline into the severe impairment band, makes amantadine accumulation the primary diagnosis; reducing levodopa without addressing the pharmacokinetic cause treats the wrong drug.

ANSWER: E

Rationale:

This case illustrates a clinically important pharmacokinetic transition: the removal of a strong CYP3A4 inducer from a regimen that had been calibrated around that induction. Rifampin is one of the most potent known CYP3A4 inducers; its co-administration dramatically increases CYP3A4 activity, accelerating istradefylline catabolism and reducing plasma concentrations. The 40 mg dose was selected in part to maintain therapeutic istradefylline exposure in the face of this induction. When rifampin is discontinued, the CYP3A4 induction effect wanes over approximately one to two weeks as the enzyme activity normalizes. As CYP3A4 activity returns toward baseline, istradefylline clearance decreases and plasma concentrations rise — in this patient, from the compensated level during rifampin co-administration toward concentrations that are now supraphysiological for a patient without an inducer. The elevated concentrations produce pharmacodynamic adverse effects: hallucinations through limbic circuit effects, and worsening dyskinesia through the expected pharmacodynamic consequence of enhanced indirect pathway disinhibition amplifying net motor drive. Azithromycin, a macrolide antibiotic, is a moderate CYP3A4 inhibitor at high doses but is not a potent inducer like rifampin — it does not replace rifampin's inductive effect. The correct response is to reduce the istradefylline dose to 20 mg once daily, the standard therapeutic dose in the absence of CYP3A4 induction, and monitor for resolution of adverse effects. Option E correctly identifies the removal of CYP3A4 induction as the mechanism, the consequence of rising plasma concentrations, and the correct dose reduction.

• Option A: Option A is incorrect; azithromycin is not a CYP3A4 inducer and does not replace rifampin's inductive effect — the mechanism of deterioration is rising istradefylline concentrations from lost induction, not a withdrawal phenomenon.
• Option B: Option B is incorrect; the precise temporal relationship between rifampin discontinuation and symptom onset, consistent with the two-week timeline for CYP3A4 activity normalization after rifampin withdrawal, makes pharmacokinetic drug interaction the correct diagnosis rather than coincidental disease progression.
• Option C: Option C is incorrect; while azithromycin has some moderate CYP3A4 inhibitory activity, the dominant pharmacokinetic change is loss of rifampin's induction rather than new inhibition by azithromycin; complete discontinuation is more aggressive than necessary — dose reduction to 20 mg is the appropriate step.
• Option D: Option D is incorrect; rifampin has no established direct neuroprotective effect on dopaminergic neurons relevant to this clinical context, and this mechanistic explanation is fabricated.

ANSWER: B

Rationale:

The three-way differential between anticholinergic toxidrome, NMS, and serotonin syndrome is a high-stakes clinical discrimination exercise, and this case provides the key distinguishing features needed to identify anticholinergic toxidrome. Both trihexyphenidyl and amitriptyline carry significant anticholinergic activity; the accidental amitriptyline double dose has pushed the total anticholinergic burden above the threshold for frank toxidrome in a patient already on a standing anticholinergic agent. The peripheral signs — hot dry flushed skin from anhidrosis-driven hyperthermia, mydriasis from iris sphincter blockade, absent bowel sounds from GI smooth muscle blockade, urinary retention from detrusor blockade, tachycardia from cardiac M2 blockade — are the hallmarks of systemic muscarinic receptor blockade. The two critical negative findings that complete the differential are: the absence of lead-pipe muscular rigidity (which is required for NMS and its accompanying elevated creatine kinase) and the absence of neuromuscular excitability signs — clonus, hyperreflexia, myoclonus — which are required for serotonin syndrome. NMS requires exposure to a dopamine-blocking agent and presents with severe rigidity; serotonin syndrome presents with neuromuscular hyperexcitability including clonus and hyperreflexia. Anticholinergic toxidrome presents with muscular hypotonia or normal tone and depressed reflexes relative to the agitated state. Treatment includes discontinuing both anticholinergic agents and supportive care; physostigmine can be considered for severe central toxicity. Option B correctly identifies the syndrome and articulates the distinguishing features from both NMS and serotonin syndrome.

• Option A: Option A is incorrect; NMS requires dopamine receptor blockade as the precipitant — amitriptyline has very weak D2 antagonist activity insufficient to cause NMS, and the absence of rigidity is not simply an early presentation feature but a fundamental distinguishing characteristic.
• Option C: Option C is incorrect; serotonin syndrome requires neuromuscular excitability signs — clonus, hyperreflexia, myoclonus — which are absent in this patient; trihexyphenidyl does not have serotonergic agonist activity.
• Option D: Option D is incorrect; the three syndromes can and must be distinguished clinically, because their treatments differ significantly and empirical combined therapy is not standard of care.
• Option E: Option E is incorrect; the syndrome described is not a levodopa-amitriptyline dopaminergic interaction — levodopa is not mentioned in this patient's medications, and dopaminergic hyperstimulation does not produce the specific constellation of anticholinergic peripheral signs present here.

ANSWER: D

Rationale:

ESRD and dialysis dependence constitute an absolute contraindication to Gocovri (amantadine ER) at any dose. Amantadine is renally eliminated, and in ESRD its half-life is markedly prolonged; accumulation to concentrations producing CNS and other toxicity is unavoidable even at the lowest available dose. The prescribing information explicitly lists end-stage renal disease (CrCl below 15 mL/min) as a contraindication, and this dialysis-dependent patient falls squarely within it. The clinical challenge this creates is real: levodopa-induced dyskinesia is a significant quality-of-life problem, Gocovri is the only drug with a specific FDA indication for this indication, and removing it as an option leaves the clinician with a limited set of alternatives. Levodopa dose reduction reduces dyskinesia but at the cost of increased off-time and worsened motor function during on-periods. Levodopa continuous intestinal infusion (Duopa) or continuous subcutaneous infusion systems can smooth the plasma concentration fluctuations that drive peak-dose dyskinesia, though availability and patient acceptability vary. Deep brain stimulation (DBS) of the subthalamic nucleus effectively reduces dyskinesia and is the most durable solution for appropriate surgical candidates. Option D correctly identifies the contraindication and outlines the realistic alternative strategies.

• Option A: Option A is incorrect; ESRD is a contraindication to Gocovri at any dose including 68.5 mg — there is no approved renally adjusted dose for ESRD, and dialysis does not provide sufficient clearance to make any dose safe.
• Option B: Option B is incorrect; istradefylline's indication is off-time reduction, not dyskinesia — prescribing it as a dyskinesia agent misapplies its approved indication, regardless of its renal independence.
• Option C: Option C is incorrect; immediate-release amantadine is not considered safe in ESRD simply because hemodialysis removes some amantadine — the clearance provided by dialysis is insufficient to prevent accumulation to toxic levels between sessions, and this approach is not supported by the amantadine prescribing information for ESRD.
• Option E: Option E is incorrect; Osmolex ER contains the same amantadine molecule as Gocovri and carries the same renal contraindications — its osmotic release mechanism does not alter the pharmacokinetic basis of the ESRD contraindication, which is about amantadine elimination, not absorption.

ANSWER: A

Rationale:

This case presents a clear signal of istradefylline-associated impulse control disorder that requires immediate action. Several features of the presentation converge to make istradefylline the most likely precipitant: the behavior emerged three weeks into istradefylline therapy, consistent with the timeframe of pharmacodynamic adverse effects; the patient has a documented prior ICD from pramipexole that fully resolved with drug discontinuation, establishing that she has ICD vulnerability; and istradefylline specifically carries a warning for ICDs in its prescribing information. The prior resolution of ICD after pramipexole removal confirms that the ICD was drug-induced rather than intrinsic to her PD, making recurrence with a second agent that carries the same warning highly plausible. The management priorities are: discontinue istradefylline; establish financial safeguards (access controls on credit cards, online accounts) to limit harm while the behavior resolves; counsel the patient and family about the mechanism, expected resolution with drug removal, and need to disclose this history before any future prescribing of dopaminergic or ICD-risk agents; and weigh the risk of re-initiating istradefylline given that she has now shown ICD vulnerability to two agents through different mechanisms. Option A correctly identifies istradefylline as the likely precipitant, addresses the management priorities comprehensively, and raises the important prescribing history consideration.

• Option B: Option B is incorrect; istradefylline's A2A mechanism does not directly engage the D3 mesolimbic pathway, but the drug's prescribing information specifically lists ICDs as a recognized adverse effect — mechanistic independence from the D3 pathway does not exclude ICD causation, and dismissing istradefylline as non-implicated ignores its own warning.
• Option C: Option C is incorrect; the behavior described — spending hours daily on compulsive purchasing, making uncontrolled large purchases, and concealing behavior — meets clinical criteria for ICD regardless of whether it has caused financial ruin; minimizing the presentation delays appropriate management.
• Option D: Option D is incorrect; uptitrating the suspected causative agent in a patient actively demonstrating ICD behavior amplifies the risk — increasing istradefylline dose is contraindicated in this setting.
• Option E: Option E is incorrect; quetiapine is used in PD for dopaminergic psychosis and hallucinations but is not the standard treatment for ICD — removing the causative agent is the primary intervention, and suppressing ICD behavior with an antipsychotic while continuing the causative drug treats the symptom rather than the cause.

ANSWER: C

Rationale:

This case requires distinguishing two concurrent findings with different clinical significance. Livedo reticularis is a well-recognized and benign adverse effect of amantadine — a reversible mottled vasospastic skin discoloration caused by cutaneous vasospasm — that does not indicate systemic disease, does not require drug discontinuation, and resolves when amantadine is stopped. It is cosmetically distressing but not medically dangerous. The patient's distress about the appearance warrants acknowledgment and a discussion of the option to discontinue if she prioritizes cosmetic appearance over dyskinesia benefit. The bilateral pitting edema is a different matter entirely. Peripheral edema is listed as an adverse effect of amantadine, but edema of 2+ severity to mid-calf in a patient with hypertension is not attributable to amantadine alone without excluding other causes. Hypertensive heart disease, early congestive heart failure, hepatic disease, and renal disease are all causes of dependent edema that could coexist with amantadine use and that would require separate management. The appropriate response is to evaluate the edema with clinical assessment and targeted workup (BNP or NT-proBNP, renal function, liver function, echocardiography if indicated) before attributing it solely to amantadine, and to assess the overall benefit-risk balance of Gocovri given that two adverse effects have now emerged. Option C correctly distinguishes the two findings and prescribes the appropriate separate management approach for each.

• Option A: Option A is incorrect; while both livedo reticularis and edema can occur with amantadine, they do not share the same mechanism — livedo is vasospastic while edema has multiple potential causes in this patient that require evaluation.
• Option B: Option B is incorrect; attributing the edema solely to hypertension without evaluation misses the possibility of amantadine as a contributing cause and the need to exclude cardiac, hepatic, or renal pathology.
• Option D: Option D is incorrect; livedo reticularis from amantadine is not a precursor to vasculitis or skin ulceration — it is a benign vasospastic phenomenon, and the edema does not confirm systemic vascular involvement.
• Option E: Option E is incorrect; livedo reticularis is not a reliable pharmacokinetic marker of supratherapeutic amantadine plasma concentrations and cannot be used to guide dose titration — it occurs across a range of therapeutic concentrations.

ANSWER: E

Rationale:

The identification of MCI in a patient on a long-term anticholinergic agent creates both a prescribing obligation and a clinical opportunity. The prescribing obligation is clear: cognitive impairment of any degree is a contraindication to anticholinergic use in PD, because central muscarinic blockade compounds the already-impaired cortical and hippocampal cholinergic function that underlies PD-associated cognitive decline. Continuing trihexyphenidyl in a patient with confirmed MCI perpetuates a pharmacologically unnecessary and avoidable contributor to cognitive impairment. The clinical opportunity is that if the MCI has a significant pharmacological component from anticholinergic drug burden, removing the drug may produce measurable cognitive improvement — a genuinely reversible contribution to what might otherwise be framed as inevitable disease progression. This possibility makes discontinuation important not only from a safety standpoint but as a diagnostic test: cognitive reassessment three to six months after full discontinuation can help determine how much of the decline was drug-related versus disease-related. The taper approach is necessary to avoid withdrawal symptoms and tremor rebound, even given the clinical urgency. The patient needs honest counseling that improvement is possible but not guaranteed, because PD carries intrinsic cognitive risk independent of medications. Option E correctly frames the clinical urgency, mandates the taper approach, and provides realistic counseling expectations.

• Option A: Option A is incorrect; anticholinergic-related cognitive impairment has a pharmacological component that can be at least partially reversed by drug removal — continuing the drug while starting a cholinesterase inhibitor treats the downstream consequence without addressing the pharmacological cause.
• Option B: Option B is incorrect; abrupt discontinuation risks anticholinergic withdrawal syndrome and tremor rebound — the urgency of the clinical situation does not override the need for a taper, and anticholinergic exposure does not cause irreversible hippocampal neuron loss in the manner suggested.
• Option C: Option C is incorrect; anticholinergics at standard clinical doses can and do produce neuropsychological test abnormalities, particularly in patients with PD who have reduced baseline cholinergic reserve — dismissing the drug as non-contributory without a trial of discontinuation is pharmacologically indefensible.
• Option D: Option D is incorrect; there is no documentation that the patient had MCI before starting trihexyphenidyl — the cognitive decline emerged during the four years of treatment, and attributing it entirely to PD progression without first removing the anticholinergic does not meet the standard of clinical care.

ANSWER: B

Rationale:

Istradefylline is metabolized primarily by CYP1A1 and CYP3A4, with a minor contribution from CYP1A2. Fluvoxamine is pharmacologically unusual among SSRIs in being both a potent inhibitor of CYP1A2 and a moderate inhibitor of CYP3A4 — a profile that distinguishes it from most other SSRIs which have minimal CYP3A4 activity. The moderate CYP3A4 inhibition by fluvoxamine is the clinically relevant interaction for istradefylline: by reducing CYP3A4 metabolic capacity, fluvoxamine decreases istradefylline clearance and raises its steady-state plasma concentrations. This is not a dramatic interaction — moderate CYP3A4 inhibition produces a less pronounced concentration increase than potent inhibitors such as ketoconazole — but in a patient whose plasma concentrations were already calibrated to the therapeutic threshold at 20 mg, even a moderate rise can push concentrations into the adverse effect range, producing hallucinations through enhanced limbic circuit disinhibition and worsening dyskinesia through increased net motor drive. The appropriate response is to reduce the istradefylline dose, assess whether the adverse effects resolve with lower exposure, and consider whether the combination can be managed at a reduced istradefylline dose or whether one drug must be substituted. Option B correctly identifies CYP3A4 inhibition as the relevant mechanism and describes appropriate management.

• Option A: Option A is incorrect; istradefylline is not meaningfully metabolized by CYP2D6, and fluvoxamine's CYP2D6 inhibitory activity is not the clinically relevant pathway for this interaction; additionally, a 10 mg istradefylline dose does not exist in the approved regimen.
• Option C: Option C is incorrect; CYP1A2 makes only a minor contribution to istradefylline metabolism — the primary routes are CYP1A1 and CYP3A4, so characterizing the interaction as exclusively CYP1A2-mediated misrepresents the drug's metabolic profile; furthermore, entacapone is a COMT inhibitor for wearing-off, not an A2A antagonist.
• Option D: Option D is incorrect; fluvoxamine is a clinically significant CYP3A4 inhibitor — characterizing SSRIs as a class as lacking CYP3A4 activity overlooks fluvoxamine's specific enzyme inhibition profile; the symptoms are pharmacokinetically explained and do not represent serotonin syndrome, which requires neuromuscular excitability signs.
• Option E: Option E is incorrect; there is no established serotonin-adenosine receptor cross-talk mechanism causing pharmacodynamic interaction between fluvoxamine and istradefylline — this mechanistic explanation is fabricated, and the interaction is pharmacokinetic, not pharmacodynamic.

ANSWER: D

Rationale:

This patient requires careful integration of multiple clinical constraints to arrive at the correct pharmacological decision. The primary functionally limiting problem is dyskinesia — the inability to dress independently — which defines the therapeutic priority. The correct agent for levodopa-induced dyskinesia is Gocovri (amantadine ER), which carries the specific FDA indication for this indication. The renal constraint is critical: his CrCl of 38 mL/min falls in the 30 to 59 mL/min range, which requires dose reduction to 68.5 mg at bedtime — the full 137 mg dose is not approved at this renal function level. The cognitive constraint is also critical: MCI is not a contraindication to amantadine ER — unlike anticholinergics, which are absolutely contraindicated in MCI — but amantadine ER can itself cause hallucinations and cognitive adverse effects, particularly in patients with reduced cognitive reserve. This creates a monitoring obligation: baseline neuropsychiatric and cognitive assessment before initiation, the standard one-week titration at 68.5 mg before considering uptitration, and active surveillance for neuropsychiatric adverse effects throughout treatment. The wearing-off can be addressed separately: entacapone and levodopa dose optimization are appropriate first steps, and istradefylline is a reasonable next consideration if wearing-off remains after dyskinesia is controlled. Option D correctly prioritizes the dyskinesia problem, applies the renal dose adjustment, identifies amantadine ER as appropriate despite MCI (with monitoring requirements), and defers wearing-off management appropriately.

• Option A: Option A is incorrect; istradefylline's indication is off-time reduction, not dyskinesia — prescribing it for the more functionally limiting complaint (dyskinesia) misapplies its approved indication.
• Option B: Option B is incorrect; anticholinergics are contraindicated in patients with MCI — the cognitive risk is not "acceptable at low doses" when a formal contraindication exists; furthermore, anticholinergics have no established antidyskinetic mechanism.
• Option C: Option C is incorrect; the standard 137 mg dose is not appropriate for a CrCl of 38 mL/min — the approved prescribing information requires dose reduction to 68.5 mg for CrCl 30 to 59 mL/min.
• Option E: Option E is incorrect; ropinirole reduction can modestly reduce dyskinesia but is not the recommended primary approach when a drug with a specific dyskinesia indication is available — and reducing dopamine agonist therapy risks worsening motor function and increasing off-time without reliably eliminating established dyskinesia.

ANSWER: A

Rationale:

This case illustrates a clinically important and underrecognized hazard: abrupt discontinuation of high-dose long-term anticholinergic therapy in a patient with PD can precipitate an NMS-like syndrome through a mechanism distinct from true NMS. In PD, the motor system is maintained by a carefully calibrated balance of dopaminergic and cholinergic signaling in the striatum. Trihexyphenidyl has been providing muscarinic blockade that partially corrects the relative cholinergic excess in this patient's dopamine-depleted striatum. When it is stopped abruptly after eight years at a high dose, cholinergic rebound occurs: suddenly unrestrained cholinergic activity further disrupts the already-impaired dopaminergic signaling of the direct and indirect pathways. The result is acute severe worsening of parkinsonian motor function — rigidity, akinesia — combined with autonomic instability from the cholinergic rebound itself, producing hyperthermia (partly from immobility and partly from autonomic dysregulation), diaphoresis, tachycardia, and confusion. The elevated CK reflects muscle breakdown from severe rigidity and immobility. This syndrome is mechanistically distinct from true NMS, which requires exposure to a dopamine-blocking agent as the precipitant. The correct treatment is prompt reinstatement of trihexyphenidyl — not dantrolene or bromocriptine — to restore the dopaminergic-cholinergic balance, followed by supportive care for the complications of acute severe immobility. A plan for gradual tapering of the anticholinergic should be formulated before the patient is discharged. Option A correctly identifies the anticholinergic withdrawal mechanism, the NMS-like presentation, and the appropriate management.

• Option B: Option B is incorrect; pramipexole is a dopamine agonist, not an antagonist — it does not cause NMS through dopamine receptor blockade, and the correct treatment for this presentation is anticholinergic reinstatement rather than dopaminergic withdrawal.
• Option C: Option C is incorrect; anticholinergic toxidrome results from drug excess, not drug withdrawal — stopping trihexyphenidyl produces cholinergic rebound, not anticholinergic toxidrome, and there are no stored tissue depots that release drug upon discontinuation.
• Option D: Option D is incorrect; while rhabdomyolysis is a complication of severe immobility from worsened parkinsonism, dismissing the NMS-like syndrome as simple rhabdomyolysis and withholding trihexyphenidyl fails to address the underlying cause — reinstatement of the anticholinergic is the essential intervention.
• Option E: Option E is incorrect; the distinction between anticholinergic withdrawal syndrome and true NMS is not merely academic — the treatments are fundamentally different; administering bromocriptine and dantrolene without reinstating trihexyphenidyl treats the wrong diagnosis and delays the correct intervention.